Please select the option that best describes you:
Do you constrain the dose to the oropharynx, parotids, or oral cavity when planning HA-WBRT?
A HA-WBRT patient developed brisk mucositis on the soft palate at fraction 8/10
Answer from: Radiation Oncologist at Community Practice
On NRG CC001, there was no inter-arm difference in reported adverse events of oral mucositis (N=6 on conventional WBRT arm vs. N=4 on HA-WBRT arm), oral pain (N=3 on conventional WBRT arm vs. N=1 on HA-WBRT arm ), or dry mouth (N=19 on conventional WBRT arm vs. N=18 on HA-WBRT arm) (Brown et al., PM...
Sign in or Register to read more